M Montemurro

Summary

Affiliation: Centre Hospitalier Universitaire Vaudois
Country: Switzerland

Publications

  1. ncbi Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkol
    M Montemurro
    Department of Internal Medicine C, Hematology and Oncology, Stem Cell Transplantation, Ernst Moritz Arndt University, Sauerbruchstrasse, 17475 Greifswald, Germany
    Ann Oncol 18:665-71. 2007
  2. ncbi [Systemic treatment of metastatic colorectal cancer]
    M Montemurro
    Centre Pluridisciplinaire d Oncologie, CHUV, Lausanne
    Rev Med Suisse 4:1254-7. 2008
  3. ncbi Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib
    M Montemurro
    University Hospital Lausanne, Cancer Center, Lausanne, Switzerland
    Eur J Cancer 45:2293-7. 2009
  4. ncbi Treatment of gastrointestinal stromal tumor after imatinib and sunitinib
    Michael Montemurro
    Comprehensive Cancer Center, University Hospital Lausanne Chuv, Lausanne, Switzerland
    Curr Opin Oncol 23:367-72. 2011
  5. ncbi Long-term follow-up of high-dose chemotherapy with autologous stem-cell transplantation and response-adapted whole-brain radiotherapy for newly diagnosed primary CNS lymphoma: results of the multicenter Ostdeutsche Studiengruppe Hamatologie und Onkologie
    T Kiefer
    Department of Internal Medicine C, Haematology and Oncology, Stem Cell Transplantation, Ernst Moritz Arndt University, Greifswald, Germany
    Ann Oncol 23:1809-12. 2012
  6. ncbi Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry
    A Haouala
    Division de pharmacologie clinique, Departement de Medecine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    J Chromatogr B Analyt Technol Biomed Life Sci 877:1982-96. 2009
  7. ncbi Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis
    M Montemurro
    Centre Pluridisciplinaire d Oncologie, University Hospital Lausanne, Lausanne, Switzerland
    Eur J Cancer 49:1027-31. 2013
  8. ncbi [Anti-angiogenic therapies for metastatic colorectal, breast and lung cancer: benefits and risks]
    A D Wagner
    Centre Pluridisciplinaire d Oncologie, CHUV, Lausanne
    Rev Med Suisse 6:1070-3. 2010
  9. ncbi [Management of hepatocellular carcinoma]
    I Pache
    Service de gastro entérologie et d hépatologie, CHUV, Lausanne
    Rev Med Suisse 6:198-202. 2010

Collaborators

Detail Information

Publications9

  1. ncbi Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkol
    M Montemurro
    Department of Internal Medicine C, Hematology and Oncology, Stem Cell Transplantation, Ernst Moritz Arndt University, Sauerbruchstrasse, 17475 Greifswald, Germany
    Ann Oncol 18:665-71. 2007
    ....
  2. ncbi [Systemic treatment of metastatic colorectal cancer]
    M Montemurro
    Centre Pluridisciplinaire d Oncologie, CHUV, Lausanne
    Rev Med Suisse 4:1254-7. 2008
    ..This article resumes recent therapeutic advances in the field and emphasizes the multidisciplinary concertation between specialists to obtain the best outcome...
  3. ncbi Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib
    M Montemurro
    University Hospital Lausanne, Cancer Center, Lausanne, Switzerland
    Eur J Cancer 45:2293-7. 2009
    ..Nilotinib is active in GIST resistant to both imatinib and sunitinib. These results warrant further investigation of nilotinib in GIST...
  4. ncbi Treatment of gastrointestinal stromal tumor after imatinib and sunitinib
    Michael Montemurro
    Comprehensive Cancer Center, University Hospital Lausanne Chuv, Lausanne, Switzerland
    Curr Opin Oncol 23:367-72. 2011
    ..Unfortunately, treatment failure and tumor progression seem inevitable over time and constitute an unresolved clinical challenge. This article reviews current efforts to overcome drug resistance and progression...
  5. ncbi Long-term follow-up of high-dose chemotherapy with autologous stem-cell transplantation and response-adapted whole-brain radiotherapy for newly diagnosed primary CNS lymphoma: results of the multicenter Ostdeutsche Studiengruppe Hamatologie und Onkologie
    T Kiefer
    Department of Internal Medicine C, Haematology and Oncology, Stem Cell Transplantation, Ernst Moritz Arndt University, Greifswald, Germany
    Ann Oncol 23:1809-12. 2012
    ..Now, we update the initial results...
  6. ncbi Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry
    A Haouala
    Division de pharmacologie clinique, Departement de Medecine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    J Chromatogr B Analyt Technol Biomed Life Sci 877:1982-96. 2009
    ....
  7. ncbi Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis
    M Montemurro
    Centre Pluridisciplinaire d Oncologie, University Hospital Lausanne, Lausanne, Switzerland
    Eur J Cancer 49:1027-31. 2013
    ..Smaller trials in this setting suggested activity for sorafenib, a multikinase inhibitor of receptor tyrosine kinases and RAF serine/threonine kinases...
  8. ncbi [Anti-angiogenic therapies for metastatic colorectal, breast and lung cancer: benefits and risks]
    A D Wagner
    Centre Pluridisciplinaire d Oncologie, CHUV, Lausanne
    Rev Med Suisse 6:1070-3. 2010
    ..A summary of the data concerning anti-angiogenic therapies in these three cancers is presented including safety information...
  9. ncbi [Management of hepatocellular carcinoma]
    I Pache
    Service de gastro entérologie et d hépatologie, CHUV, Lausanne
    Rev Med Suisse 6:198-202. 2010
    ..A multidisciplinary approach is mandatory to offer to each patient the best treatment...